Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18591749 | 0.94 | CACNA1H (0.47) | CACNA1HCARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL19961023 | 0.88 | CARM1 (0.50) | CACNA1HCARM1PRMT6PRMT8MEN1 | |
| SCHEMBL10192177 | 0.84 | CARM1 (0.56) | CACNA1HCARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL23922127 | 0.84 | CACNA1H (0.49) | CACNA1HCARM1PRMT6PRMT8MEN1 | |
| SCHEMBL22959615 | 0.84 | POLB (0.41) | CARM1PRMT6PRMT8SIGMAR1POLB | |
| SCHEMBL20317549 | 0.83 | CACNA1H (0.41) | CACNA1HCARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL18591725 | 0.83 | SMN1; SMN2 (0.39) | CACNA1HSIGMAR1ACE2ALDH1A1SMN1; SMN2 | |
| SCHEMBL13137785 | 0.82 | CARM1 (0.54) | CACNA1HCARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL7745180 | 0.82 | CARM1 (0.54) | CACNA1HCARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL12025008 | 0.82 | CARM1 (0.39) | CARM1PRMT6PRMT8SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | CACNA1H 4862/4885CARM1 1309/4885PRMT6 1183/4885 |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CACNA1H 4695/4885CARM1 1051/4885PRMT6 631/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | CACNA1H 4459/4885CARM1 1030/4885PRMT6 970/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | CACNA1H 4806/4885CARM1 871/4885PRMT6 572/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | CACNA1H 4286/4885CARM1 1628/4885PRMT6 1486/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | CACNA1H 4669/4885CARM1 712/4885PRMT6 849/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | CACNA1H 4431/4885CARM1 1251/4885PRMT6 494/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | CACNA1H 4669/4885CARM1 712/4885PRMT6 849/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CACNA1H 4695/4885CARM1 1051/4885PRMT6 631/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | CACNA1H 4689/4885CARM1 1134/4885PRMT6 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.